drugset
drugset / Trial / NCT04311710

A Study Evaluating the Drug Levels of Iplimumab Given Under the Skin Alone and in Combination With Nivolumab in Multiple Tumor Types

NCT04311710 ↗

Phase 1 Terminated 21 enrolled Bristol-Myers Squibb
Non-randomizedSequentialOpen-labelTreatment

Summary

A study evaluating the drug levels of ipilimumab alone and in combination with nivolumab applied under the skin in various tumor types

Timeline

Start
2020-06-25
Primary completion
2021-01-14
Completion
2023-01-18

Drugs

EvaluationDrugModalityDoseRoute
Subject Ipilimumab Monoclonal antibody — Subcutaneous
Subject Nivolumab Monoclonal antibody — Subcutaneous
Background rHuPH20 Protein / enzyme biologic — —

Indications

neoplasm